Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.

Abstract

The authors would like to note the replacement of Fig.2b, for which Fig. 2a was placed erringly, with appropriate Fig. 2b.